2465 related articles for article (PubMed ID: 33707363)
1. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.
Senapati S; Banerjee P; Bhagavatula S; Kushwaha PP; Kumar S
J Genet; 2021; 100(1):. PubMed ID: 33707363
[TBL] [Abstract][Full Text] [Related]
2. Comparative analyses of ACE2 and TMPRSS2 gene: Implications for the risk to which vertebrate animals are susceptible to SARS-CoV-2.
Huang C; Jiang Y; Yan J
J Med Virol; 2021 Sep; 93(9):5487-5504. PubMed ID: 33974296
[TBL] [Abstract][Full Text] [Related]
3. An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(7):571-596. PubMed ID: 33463470
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation.
Hörnich BF; Großkopf AK; Schlagowski S; Tenbusch M; Kleine-Weber H; Neipel F; Stahl-Hennig C; Hahn AS
J Virol; 2021 Apr; 95(9):. PubMed ID: 33608407
[TBL] [Abstract][Full Text] [Related]
5. Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19.
Muralidar S; Gopal G; Visaga Ambi S
J Med Virol; 2021 Sep; 93(9):5260-5276. PubMed ID: 33851732
[TBL] [Abstract][Full Text] [Related]
6. ACE2, TMPRSS2, and Furin variants and SARS-CoV-2 infection in Madrid, Spain.
Torre-Fuentes L; Matías-Guiu J; Hernández-Lorenzo L; Montero-Escribano P; Pytel V; Porta-Etessam J; Gómez-Pinedo U; Matías-Guiu JA
J Med Virol; 2021 Feb; 93(2):863-869. PubMed ID: 32691890
[TBL] [Abstract][Full Text] [Related]
7. Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2.
Suryamohan K; Diwanji D; Stawiski EW; Gupta R; Miersch S; Liu J; Chen C; Jiang YP; Fellouse FA; Sathirapongsasuti JF; Albers PK; Deepak T; Saberianfar R; Ratan A; Washburn G; Mis M; Santhosh D; Somasekar S; Hiranjith GH; Vargas D; Mohan S; Phalke S; Kuriakose B; Antony A; Ustav M; Schuster SC; Sidhu S; Junutula JR; Jura N; Seshagiri S
Commun Biol; 2021 Apr; 4(1):475. PubMed ID: 33846513
[TBL] [Abstract][Full Text] [Related]
8. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
[TBL] [Abstract][Full Text] [Related]
9. Variants in ACE2; potential influences on virus infection and COVID-19 severity.
Bakhshandeh B; Sorboni SG; Javanmard AR; Mottaghi SS; Mehrabi MR; Sorouri F; Abbasi A; Jahanafrooz Z
Infect Genet Evol; 2021 Jun; 90():104773. PubMed ID: 33607284
[TBL] [Abstract][Full Text] [Related]
10. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
11. Target-Centered Drug Repurposing Predictions of Human Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Protease Serine Subtype 2 (TMPRSS2) Interacting Approved Drugs for Coronavirus Disease 2019 (COVID-19) Treatment through a Drug-Target Interaction Deep Learning Model.
Choi Y; Shin B; Kang K; Park S; Beck BR
Viruses; 2020 Nov; 12(11):. PubMed ID: 33218024
[TBL] [Abstract][Full Text] [Related]
12. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
Choudhary S; Silakari O
Virus Res; 2020 Nov; 289():198146. PubMed ID: 32866534
[TBL] [Abstract][Full Text] [Related]
13. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein.
Heurich A; Hofmann-Winkler H; Gierer S; Liepold T; Jahn O; Pöhlmann S
J Virol; 2014 Jan; 88(2):1293-307. PubMed ID: 24227843
[TBL] [Abstract][Full Text] [Related]
14. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
15. Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2.
Ahmad S; Waheed Y; Abro A; Abbasi SW; Ismail S
J Mol Model; 2021 Jun; 27(7):206. PubMed ID: 34169390
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 infection susceptibility influenced by ACE2 genetic polymorphisms: insights from Tehran Cardio-Metabolic Genetic Study.
Lanjanian H; Moazzam-Jazi M; Hedayati M; Akbarzadeh M; Guity K; Sedaghati-Khayat B; Azizi F; Daneshpour MS
Sci Rep; 2021 Jan; 11(1):1529. PubMed ID: 33452303
[TBL] [Abstract][Full Text] [Related]
17. Priming of SARS-CoV-2 S protein by several membrane-bound serine proteinases could explain enhanced viral infectivity and systemic COVID-19 infection.
Fuentes-Prior P
J Biol Chem; 2021; 296():100135. PubMed ID: 33268377
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
19. Expression of ACE2 and TMPRSS2 Proteins in the Upper and Lower Aerodigestive Tracts of Rats: Implications on COVID 19 Infections.
Sato T; Ueha R; Goto T; Yamauchi A; Kondo K; Yamasoba T
Laryngoscope; 2021 Mar; 131(3):E932-E939. PubMed ID: 32940922
[TBL] [Abstract][Full Text] [Related]
20. Molecular Interactions of Tannic Acid with Proteins Associated with SARS-CoV-2 Infectivity.
Haddad M; Gaudreault R; Sasseville G; Nguyen PT; Wiebe H; Van De Ven T; Bourgault S; Mousseau N; Ramassamy C
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
